Rick Soni, MBA
Chief Executive Officer
Cellular Logistics, Inc.
Rick Soni has 30 years of pharmaceutical industry experience developing and commercializing highly successful products. Currently, Rick is CEO of Cellular Logistics, Inc., an early stage cardiac regenerative medicine company. Rick is also an Advisor to Therabron Therapeutics, a clinical stage company developing new class of respiratory drugs based upon secretoglobin family of proteins.
Previously, Rick worked as President and Chief Operating Officer of Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing Oncology therapeutics. While at Rexahn, Rick was instrumental in transforming Rexahn from a discovery company to a clinical stage company. Under his leadership, Rexahn formed major partnerships with Teva Pharmaceuticals as well as many Universities in North America, Europe and Asia. Rick also built strong relationships between Rexahn and various investors resulting in approximately $60 million equity investment in Rexahn.
Prior to joining Rexahn, Rick held various management positions within Otsuka from June 1997 until July 2008 and was responsible for development and commercialization of otsuka’s successful product portfolio. He was also instrumental in laying the foundation of a Medical Device Division within Otsuka. Prior to Otsuka, Rick held several management roles within New Product Planning, Sales and Marketing at Novartis and Schering-Plough (now Merck).
Rick has participated in several panel discussions pertaining to Life Sciences Industry. From 2013- 2015, he was also selected as one of the judges for prestigious Medical Marketing& Media Awards. He is a Commercial Advisory Board member for Bio Health Innovation (BHI), a nonprofit private/public partnership dedicated to commercializing various innovative technologies.
Company website: www.Cellogistics.com
Cell: (301) 938-1663